newsfilter
← Earnings
Earnings Releases·

Cogent Biosciences — Third Quarter 2026 Earnings Summary

Cogent Biosciences reported a net loss of $111.4 million for the third quarter of 2026, driven by increased research and development and general and administrative expenses. The company maintains a cash balance of $791.1 million, which is projected to fund operations into late 2028. Key regulatory milestones include the anticipated PDUFA action dates for bezuclastinib in GIST on November 30, 2026, in NonAdvanced Systemic Mastocytosis on December 30, 2026, and in Advanced Systemic Mastocytosis on June 29, 2027. Additionally, the company plans to submit Investigational New Drug applications for its JAK2 and KRAS pipeline programs in the fourth quarter of 2026.

Company
COGENT BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology